SCHEMBL26670516

SCHEMBL26670516

Cc1nn2ccc(OCc3ccccc3F)cc2c1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.44
ALKBH1 Q13686 2/20 0.43
PARP15 Q460N3 3/20 0.43
PARP10 Q53GL7 3/20 0.43
PARP14 Q460N5 1/20 0.42
GCK P35557 2/20 0.41
KCNH2 Q12809 1/20 0.41
RARA P10276 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
HPD P32754 1/20 0.41
PTPN1 P18031 1/20 0.41
SLC26A4 O43511 1/20 0.40
KDM5A P29375 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
POLB P06746 1/20 0.40
LPAR1 Q92633 1/20 0.40
LPAR5 Q9H1C0 1/20 0.40
NPC1 O15118 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26670490 0.89 KMT2A (0.45) MAOBPARP15PARP10PARP14KCNH2
SCHEMBL26670510 0.87 MEN1 (0.53) MAOBALKBH1GCKSLC26A4NPC1
SCHEMBL956524 0.85 ALKBH1 (0.55) MAOBALKBH1POLB
SCHEMBL30668936 0.84 POLB (0.41) MAOBPARP15PARP10PARP14GCK
SCHEMBL26829251 0.84 POLB (0.41) MAOBPARP15PARP10PARP14GCK
SCHEMBL30668953 0.83 GUCY1B2 (0.42) MAOBPARP15PARP10PARP14GCK
SCHEMBL26829246 0.83 GUCY1B2 (0.42) MAOBPARP15PARP10PARP14GCK
SCHEMBL26670547 0.83 GUCY1B2 (0.42) MAOBPARP15PARP10GCKKCNH2
SCHEMBL30668948 0.83 PARP10 (0.41) MAOBPARP15PARP10PARP14GCK
SCHEMBL26829249 0.83 PARP10 (0.41) MAOBPARP15PARP10PARP14GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376468-A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119998280-A Pyrazolo [1,5-a ] pyridine derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-13 CN disclosed
EP-4499636-A2 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230542-A2 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023230542-A2 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376468-A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM5, TRPM4 MAOB 1982/4885ALKBH1 4636/4885PARP15 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.